A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.

This study has been withdrawn prior to enrollment.
(This study was Cancelled Before Active)
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01440361
First received: September 22, 2011
Last updated: July 24, 2014
Last verified: July 2014

September 22, 2011
July 24, 2014
March 2013
April 2015   (final data collection date for primary outcome measure)
  • Platelet count [ Time Frame: Baseline, week 28 ] [ Designated as safety issue: No ]
    Change in platelet count
  • Anti-platelet autoantibodies [ Time Frame: Baseline, week 28 ] [ Designated as safety issue: No ]
    Change in anti-platelet autoantibodies
Same as current
Complete list of historical versions of study NCT01440361 on ClinicalTrials.gov Archive Site
  • Platelet count (time) [ Time Frame: Baseline, week 0, 2, 4, 8, 12, 16, 20, 24, 28 ] [ Designated as safety issue: No ]
    Time to first response of platelet count increase >20,000/microlitre (μl) from baseline
  • Platelet count (incidence) [ Time Frame: Baseline, week 28 ] [ Designated as safety issue: No ]
    Incidence of response of platelet count increase >20,000/μL from baseline
  • Platelet count (incidence of complete response) [ Time Frame: Baseline, week 28 ] [ Designated as safety issue: No ]
    Incidence of complete response as defined by platelet count to >100,000
  • Platelet count (incidence of doubling) [ Time Frame: Baseline, week 28 ] [ Designated as safety issue: No ]
    Incidence of subjects with ≥2 times baseline platelet count
  • Vital signs [ Time Frame: Baseline, week 0, 2, 4, 8, 12, 16, 20, 24, 28, 40 ] [ Designated as safety issue: Yes ]
    Change in vital signs outside normal range
  • Clinical chemistry and haematology [ Time Frame: Baseline, week 2, 4, 8, 12, 16, 20, 24, 28, 40 ] [ Designated as safety issue: Yes ]
    Change in clinical chemistry and haematology
  • Immunogenicity [ Time Frame: Baseline, week 12, 28, 40, 52 ] [ Designated as safety issue: Yes ]
    Change in immunogenicity
  • Serum concentrations of belimumab [ Time Frame: Baseline, week 2, 8, 24, 28, 40, 52 ] [ Designated as safety issue: No ]
    Change in serum concentrations of belimumab
  • Serum and/or platelet bound anti-platelet antibodies [ Time Frame: Baseline, week 4, 8, 12, 16, 20, 24, 28, 40, 52 ] [ Designated as safety issue: No ]
    Change in serum and/or platelet bound anti-platelet antibodies
  • B cell and T cell sub-populations and B lymphocyte stimulator (BLyS) receptor [ Time Frame: Baseline, week 4, 8, 16, 24, 40, 52 ] [ Designated as safety issue: No ]
    Change in B cell and T cell sub-populations and BLyS receptor
  • Antigen-specific B cells and T cells [ Time Frame: Baseline, week 8, 16, 24, 40 ] [ Designated as safety issue: No ]
    Change in antigen-specific B cells and T cells
  • Serum cytokine/chemokine profile [ Time Frame: Baseline, week 8, 16, 24, 28, 40 ] [ Designated as safety issue: No ]
    Change in serum cytokine/chemokine profile
  • Transcriptome profile [ Time Frame: Baseline, week 8, 28 ] [ Designated as safety issue: No ]
    Change in transcriptome profile
  • Autoantibody profile [ Time Frame: Baseline, week 28 ] [ Designated as safety issue: No ]
    Change in autoantibody profile
  • Platelet count (time) [ Time Frame: Baseline, week 0, 2, 4, 8, 12, 16, 20, 24, 28 ] [ Designated as safety issue: No ]
    Time to first response of platelet count increase >20,000/μL from baseline
  • Platelet count (incidence) [ Time Frame: Baseline, week 28 ] [ Designated as safety issue: No ]
    Incidence of response of platelet count increase >20,000/μL from baseline
  • Platelet count (incidence of complete response) [ Time Frame: Baseline, week 28 ] [ Designated as safety issue: No ]
    Incidence of complete response as defined by platelet count to >100,000
  • Platelet count (incidence of doubling) [ Time Frame: Baseline, week 28 ] [ Designated as safety issue: No ]
    Incidence of subjects with ≥2 times baseline platelet count
  • Vital signs [ Time Frame: Baseline, week 0, 2, 4, 8, 12, 16, 20, 24, 28, 40 ] [ Designated as safety issue: Yes ]
    Change in vital signs outside normal range
  • Clinical chemistry and haematology [ Time Frame: Baseline, week 2, 4, 8, 12, 16, 20, 24, 28, 40 ] [ Designated as safety issue: Yes ]
    Change in clinical chemistry and haematology
  • Immunogenicity [ Time Frame: Baseline, week 12, 28, 40, 52 ] [ Designated as safety issue: Yes ]
    Change in immunogenicity
  • Serum concentrations of belimumab [ Time Frame: Baseline, week 2, 8, 24, 28, 40, 52 ] [ Designated as safety issue: No ]
    Change in serum concentrations of belimumab
  • Serum and/or platelet bound anti-platelet antibodies [ Time Frame: Baseline, week 4, 8, 12, 16, 20, 24, 28, 40, 52 ] [ Designated as safety issue: No ]
    Change in serum and/or platelet bound anti-platelet antibodies
  • B cell and T cell sub-populations and BLyS receptor [ Time Frame: Baseline, week 4, 8, 16, 24, 40, 52 ] [ Designated as safety issue: No ]
    Change in B cell and T cell sub-populations and BLyS receptor
  • Antigen-specific B cells and T cells [ Time Frame: Baseline, week 8, 16, 24, 40 ] [ Designated as safety issue: No ]
    Change in antigen-specific B cells and T cells
  • Serum cytokine/chemokine profile [ Time Frame: Baseline, week 8, 16, 24, 28, 40 ] [ Designated as safety issue: No ]
    Change in serum cytokine/chemokine profile
  • Transcriptomic profile [ Time Frame: Baseline, week 8, 28 ] [ Designated as safety issue: No ]
    Change in transcriptomic profile
  • Autoantibody profile [ Time Frame: Baseline, week 28 ] [ Designated as safety issue: No ]
    Change in autoantibody profile
Not Provided
Not Provided
 
A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.
A Clinical and Mechanistic Proof of Efficacy Study With Belimumab in Chronic Immune Thrombocytopenia (ITP) Patients.

Chronic immune thrombocytopenia (ITP) is a longterm disease in which the blood does not clot normally. This is due to a low number of blood cell fragments called platelets. Platelets clot to seal small cuts or breaks on blood vessel walls and stop bleeding. Normally the immune system makes proteins called antibodies to fight off harmful substances that enter the body. In ITP, the immune system produces antibodies that attack and destroy the body's platelets by mistake.

Patients can suffer from bleeding under the skin, nosebleeds, blood in urine or stools and in very severe cases bleeding in the brain. Patients have an increased frequency of death from bleeding complications compared to normal.

Chronic ITP is fairly rare , with an incidence of 32 new cases/million people each year.

Existing treatments work by lowering the activity of the immune system or directly increasing platelet count. These treatments do not work effectively in all patients and can have side effects. We hope that understanding how belimumab works in ITP will help in the development of future treatments for ITP and other autoimmune diseases.

We will test the safety, blood levels and effects of the study medication in people with chronic ITP. Patients will receive the study medication intravenously (through a needle inserted into a vein) and blood samples will be taken before and on several occasions afterwards.

Up to 40 patients with chronic ITP, aged 18 to 75 will participate. Approximately 11 patients will take dummy medicine instead of the study medicine neither they or their study doctor will know which one they are given. Participants will take up to 57 weeks to finish the study. They'll make 12 outpatient visits.

The study will take place in hospitals in the UK. Other sites in mainland Europe may also be initiated.

A pharmaceutical company, GlaxoSmithKline, is funding the study.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Purpura, Thrombocytopaenic, Idiopathic
  • Drug: Belimumab
    10 mg /kg given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
    Other Name: Benlysta/LymphoStat-B
  • Drug: Normal saline placebo
    Placebo given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
    Other Name: Saline
  • Experimental: Belimumab
    Reconstituted solution for intravenous infusion
    Intervention: Drug: Belimumab
  • Placebo Comparator: Normal saline
    Solution for intravenous infusion
    Intervention: Drug: Normal saline placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
April 2015
April 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female,18-75 years old
  • Chronic ITP for a minimum of 6 months with a platelet count <75,000/uL at screening and a platelet count <75,000/uL 2 to 6 months before screening
  • Stable either on no treatment or on a stable dose of corticosteroids (10 milligrams(mg)/day prednisone or prednisone equivalent or less) and/or azathioprine (100mg/day or less) for a minimum of 30 days before screening
  • Single QTc <450 milliseconds (msec); or QTc <480 msec in subjects with Bundle Branch Block
  • A female subject is eligible to participate if she is not pregnant or nursing and at least one of the following conditions apply: a. Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea. b.Child-bearing potential and agrees to use one of the contraception methods listed in the protocol

Exclusion Criteria:

  • Diagnosis of ITP is secondary to other conditions
  • Treated with any B cell targeted therapy at any time
  • Have received any of the following within 364 days prior to Day 0: Abatacept, A biologic investigational agent other than B cell targeted therapy
  • Have received any of the following within 180 days prior to Day 0: Intravenous (IV) cyclophosphamide, 3 or more courses of systemic corticosteroids for concomitant conditions
  • Have received any of the following within 90 days prior to Day 0: High dose corticosteroid for treatment of ITP, Splenectomy, plasmapheresis
  • Have received any of the following within 60 days, 5 half-lives or twice the duration of the biological effect of belimumab before Day 0: A non-biologic investigational agent, any other immunosuppressive/immunomodulatory agent with the exception of azathioprine and corticosteroids, Eltrombopag, romiplostim, any steroid injection
  • Have received any of the following within 30 days before Screening: Intravenous immunoglobulin, Corticosteroids greater than 10mg/day (prednisone or prednisone equivalent) or azathioprine more than 100 mg/day, Changes to corticosteroid or azathioprine therapy
  • Have received a live vaccine within 30 days before Day 0
  • Subject could be at risk of haemorrhage that threatens a vital organ
  • History of a major organ transplant or hematopoietic stem cell/marrow transplant
  • History of malignant neoplasm within the last 5 years, except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix
  • Required management of infections, as follows: Currently on any suppressive therapy for a chronic infection, Hospitalisation for treatment of infection within 60 days before Day 0, Use of parenteral antibiotics within 60 days before Day 0
  • Significant unstable or uncontrolled acute or chronic diseases not due to ITP or planned surgical procedure or a history of any other medical disease, laboratory abnormality, or condition that makes the subject unsuitable for the study
  • Positive screening Hepatitis C antibody result or Hepatitis B (HB) infection
  • Positive test for Human Immunodeficiency Virus (HIV) antibody at screening or historically
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) greater or equal to 2x upper limit of normal (ULN); alkaline phosphatase and bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%)
  • IgA deficiency (IgA <10mg/dL)
  • Abnormal lab results
  • Lymphocyte count <500/mm3
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy including a previous anaphylactic reaction to parenteral administration contrast agents, human or murine proteins or monoclonal antibodies
  • Evidence of serious suicide risk
  • Current drug or alcohol abuse or dependence
  • Where participation in the study would result in donation of blood or blood products >500 mL within a 56 day period
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01440361
114870
No
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP